Rejecting FDA Advice, ACIP Defers J&J COVID Vaccine Blood Clot Decision Until It Gets More Data

US FDA suggested potential risk could be managed though a change in the fact sheet, but CDC committee wants more data, which could come within a week or so, to get a better sense of the frequency of the adverse events.

Janssen vaccine and name (shutterstock)
The CDC's advisory committee is hoping a continued pause will allow for better data about the potential risks of Janssen's covid vaccine. • Source: Shutterstock

The recommended pause in administration of Janssen Biotech Inc.’s coronavirus vaccine likely will continue at least several more days while the US Centers for Disease Control and Prevention gathers additional data on cases of rare blood clots.

CDC Advisory Committee on Immunization Practices (ACIP) members want the extra time to better inform their decision on whether to...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Vaccines

More from Pink Sheet